Abstract
LX‐1031 is an oral, small molecule tryptophan 5‐hydroxylase (TPH) inhibitor that reduces serotonin (5‐HT) synthesis peripherally. It has potential for illnesses characterized by excess 5‐HT, such as diarrhea‐predominant irritable bowel syndrome (IBS‐D) and carcinoid diarrhea. In vitro, inhibition of TPH1 occurred in 10−8–10−7 mol L−1 range. In vivo in rodents, LX‐1031 has no effect on brain 5‐HT while dose‐dependently reducing 5‐HT, particularly in the small bowel. After oral LX1031 in humans, systemic exposure is very low, plasma concentrations are linear in dose range 250–750 mg q.i.d.; the median T1/2 for elimination is ∼20 h, and repeat administration for 14 days doubles Cmax. In ascending‐single‐dose and multiple‐dose (14 days) trials in healthy volunteers, LX‐1031, 2–4 g day−1 significantly reduced urinary 5‐hydroxyindoleacetic acid (5‐HIAA) starting by Day 5, and persisting over the 14 day exposure. There are no dose‐limiting toxicities in healthy subjects or remarkable adverse effects in clinical trials to date. Over a 28‐day treatment period, LX‐1031 was associated with improved weekly global scores (2/4 weeks) and improved stool consistency with lower urinary 5‐HIAA excretion. LX‐1031 appears promising for chronic diarrhea associated with increased 5‐HT expression including IBS‐D. Optimal doses, efficacy and safety in IBS clinical trials need to be fully elucidated; low systemic exposure, selectivity for TPH1 over TPH2, and lack of effect on brain 5‐HT in several species suggest that LX‐1031 is unlikely to cause affective disorders.

This publication has 53 references indexed in Scilit: